În afara temei aiqbench
Această știre a fost preluată de la o sursă pe care o urmărim, dar nu ține de domeniul AI sau cuantic, așa că nu există o perspectivă aiqbench pentru ea.
Buchang Pharmaceutical: Company Receives Drug Registration Certificate for Tomoxetine Hydrochloride Oral Solution
36Kr reports that Buchang Pharmaceutical announced the company recently received the 'Drug Registration Certificate' for Tomoxetine Hydrochloride Oral Solution, approved and issued by the National Medical Products Administration. The drug is indicated for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years and older.
Citește articolul complet pe 36KrSubiecte conexe
News
Quantum Computing Report · 7 iun. 2026
Changchun High-Tech: Leuprolide Acetate Injection Granted Drug Registration Certificate
36Kr · 8 oct. 2026
News
Quantum Computing Report · 25 iul. 2026
XtalPi Holdings Limited: XtalPi Holdings Announces 2026 Interim Results
finanznachrichten.de · 19 aug. 2026